A Review article on Diclofenac Sodium Topical gel on Osteoarthritis

Abstract

In comparison to oral NSAIDs, topical nonsteroidal anti-inflammatory drugs (NSAIDs) for osteoarthritis provide at least equivalent analgesia, improve physical function, reduce stiffness, and have fewer systemic adverse events. Topical diclofenac is one such NSAID. Although topical diclofenac has been shown to be successful in treating osteoarthritis, nothing is known about how long the medication takes to start working, how long it lasts, and what the lowest therapeutic concentration is. Localization and medication penetration are two factors that might affect these values. Diclofenac concentrations in the tissues of the joints are probably more important than those in the plasma. Despite the fact that diclofenac enters and remains in these "effect compartments" at the site I.e. The results of our study suggest that topical NSAIDs, like diclofenac, are a generally well-tolerated, safe, and effective first-line treatment option for osteoarthritis (OA) of the knee and hands. This is especially true for older patients, those with comorbid conditions, and those who are at risk for gastrointestinal, hepatic, renal, or cardiovascular systemic adverse events that are linked to oral NSAID use, especially when using high doses over an extended period of time of inflammation and medication action, no particular minimum effective concentration of the drug has been found in either synovial tissue or plasma. Recent data indicates that plasma concentrations may not be the most accurate indicator of effectiveness than a decrease in inflammatory markers. This narrative evaluation examines the data that is currently available in these fields and highlights any gaps that require more investigation.